Connor, Clark & Lunn Investment Management Ltd. Assembly Biosciences, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$1.09 - $20.4 $70,151 - $1.31 Million	-64,359 Reduced 49.6%	65,393 $85,000
Q3 2022 Nov 10, 2022	SELL	$1.7 - $20.52 $22,377 - $270,104	-13,163 Reduced 9.21%	129,752 $213,000
Q2 2022 Aug 05, 2022	SELL	$1.35 - $2.29 $29,747 - $50,460	-22,035 Reduced 13.36%	142,915 $300,000
Q1 2022 May 12, 2022	SELL	$1.46 - $2.45 $7,688 - $12,901	-5,266 Reduced 3.09%	164,950 $340,000
Q4 2021 Feb 10, 2022	BUY	$2.13 - $3.46 $29,396 - $47,751	13,801 Added 8.82%	170,216 $397,000
Q3 2021 Nov 12, 2021	BUY	$3.14 - $3.9 $14,877 - $18,478	4,738 Added 3.12%	156,415 $544,000
Q2 2021 Aug 12, 2021	BUY	$3.8 - $4.56 $49,141 - $58,969	12,932 Added 9.32%	151,677 $589,000
Q1 2021 May 13, 2021	BUY	$4.33 - $6.63 $600,765 - $919,879	138,745 New	138,745 $638,000
Q2 2020 Aug 13, 2020	SELL	$14.57 - $23.96 $233,076 - $383,288	-15,997 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$10.27 - $21.23 $164,289 - $339,616	15,997 New	15,997 $237,000

Others Institutions Holding ASMB

# of Institutions

Shares Held

16.3K

Call Options Held

Put Options Held

ETF Managers Group, LLC Summit, NJ

16.3K
Shares

$277,028
0.0% of portfolio

View Full List

About ASSEMBLY BIOSCIENCES, INC.

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

More about ASMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account